Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05743335 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine
A Phase 1 study, sponsored by Immorna Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
NCT05743335 is a Phase 1 study that has completed, run by Immorna Biotherapeutics. The registered enrollment target is 73 participants.
The verdict
NCT05743335, a Phase 1 study, has completed, sponsored by Immorna Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn about, test, and compare JCXH-221 in healthy volunteers. The main aims to answer are: * To assess the safety and tolerability of the JCXH-221 vaccine in healthy adult subjects * To identify an optimal dose for the JCXH-221 vaccine in healthy adult subjects * To assess the humoral immunogenicity of the JCXH-221 vaccine in healthy adult subjects * To characterize the cellular immunogenicity of the JCXH-221 vaccine in healthy adult subjects Participants for Phase I will be randomized to either JCXH-221 or placebo.
Interventions
- OTHER Placebo
- BIOLOGICAL JCXH-221
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2023-03-07 |
| Est. Completion | 2023-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05743335
The ClinicalTrials.gov registry entry for NCT05743335 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immorna Biotherapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05743335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05743335 about?
NCT05743335 is a clinical study titled "A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine". The goal of this clinical trial is to learn about, test, and compare JCXH-221 in healthy volunteers. The main aims to answer are: * To assess the safety and tolerability of the JCXH-221 vaccine in healthy adult subjects * To identify an optimal dose for the JCXH-221 vaccine in healthy adult subject...
What is the current status of trial NCT05743335?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2023-03-07. Estimated completion is 2023-12-01.
What interventions are being tested in trial NCT05743335?
The interventions under investigation include: Placebo (OTHER), JCXH-221 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05743335?
This trial is sponsored by Immorna Biotherapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.